Clarient Launches New Gene Mutation Test for Lung Cancer

Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.

Read more »

Frontrunners Emerge In Swine Flu Vaccine Race

Just days after the World Health Organization declared a swine flu pandemic, Fierce Biotech reports that two pharmaceutical companies are already racing to complete clinical trials of their H1N1 vaccines.

Read more »

TearLab Wins Silver Medical Design Excellence Award

TearLab Corporation of San Diego announced that its TearLab Osmolarity System has received a Silver 2009 Medical Design Excellence Award.

Read more »

Positive Results for Human Genome’s Lupus Drug Benlysta

Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.

Read more »

Less Than Two Weeks Until IN3 East

Hundreds of companies such as Bain Capital Ventures, Becton Dickinson, Covidien, DePuy Mitek Worldwide, Kimberly-Clark, Medtronic, Novartis BioVenture Fund, Quaker […]

Read more »

NeuroSearch’s Tesofensine Advances to Phase III Testing

Yesterday, OneMedPlace reported on several companies that are developing anti-obesity drugs. Another name can be added to the list.

Read more »

VIVUS’ Qnexa Shows Promise For Diabetics

VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.

Read more »

Correction: Sentinel – Symphony Medical

In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.

Read more »

HealthTronics to Buy Endocare

HealthTronics announced that it has entered into a definitive merger agreement with Endocare.

Read more »

Companies Rush to Create Swine Flu Vaccines

With flu season approaching, the U.S. federal government has earmarked nearly $1 billion for the development of swine flu vaccines.

Read more »